Physician profile
Carson Roberts
NPI 1902420789
$571.65
in general payments reported to CMS, 2019-2025
14 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.15 · 2024: $280 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.73 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $70.64 | 2024-2025 | |
| Dexcom, INC. | $49.82 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $49.31 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $44.97 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $42.65 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $37.40 | 2025 | Airsupra, Breztri |
| Abbott Laboratories | $36.74 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $29.37 | 2024-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $28.88 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $22.08 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.74 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $13.99 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.